With flibanserin approval, a complicated drug takes the spotlight

Whether the “little pink pill” is a boon or a boondoggle depends on who you ask

Addyi (flibanserin)

In August, the Food and Drug Administration approved Addyi (flibanserin) for the treatment of low sexual desire in women. But whether the benefits outweigh the risks depends on who you ask.

Sprout Pharmaceuticals

This article is only available to Science News subscribers.

Subscribers, enter your e-mail address to access our archives.

Not a subscriber?

Science News is a nonprofit.

Support us by subscribing now.

More Stories from Science News on Health & Medicine

From the Nature Index

Paid Content